Taro Pharmaceutical Industries Ltd.
TARO · NYSE
3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1,587,210 | $914,065 | $1,628,353 | $2,817,967 |
| - Cash | $362,909 | $154,495 | $251,134 | $605,177 |
| + Debt | $0 | $1,950 | $2,204 | $1,689 |
| Enterprise Value | $1,224,301 | $761,520 | $1,379,423 | $2,214,479 |
| Revenue | $629,182 | $572,952 | $561,347 | $548,970 |
| % Growth | 9.8% | 2.1% | 2.3% | – |
| Gross Profit | $304,979 | $268,323 | $293,122 | $296,656 |
| % Margin | 48.5% | 46.8% | 52.2% | 54% |
| EBITDA | $38,402 | $55,467 | $164,887 | -$413,775 |
| % Margin | 6.1% | 9.7% | 29.4% | -75.4% |
| Net Income | $53,867 | $25,445 | $58,266 | -$400,740 |
| % Margin | 8.6% | 4.4% | 10.4% | -73% |
| EPS Diluted | 1.43 | 0.68 | 1.55 | -10.49 |
| % Growth | 110.3% | -56.1% | 114.8% | – |
| Operating Cash Flow | $132,388 | $31,750 | -$158,698 | $45,770 |
| Capital Expenditures | -$54,218 | -$17,847 | -$12,039 | -$17,144 |
| Free Cash Flow | $78,170 | $13,903 | -$170,737 | $28,626 |